Global Liquid Biopsy Market: Industry Trends, Growth Analysis, and Forecast (2025–2033)
Introduction
The global liquid biopsy market is experiencing significant growth and is expected to reach approximately US$ 15.46 billion by 2033, compared to US$ 4.29 billion in 2024, at a robust CAGR of 15.30% from 2025 to 2033. This growth is largely attributed to the increasing demand for non-invasive cancer diagnostics, advancements in biomarker discovery, and the rising adoption of personalized medicine.
Liquid biopsy is revolutionizing the way cancers and other diseases are diagnosed and monitored. By analyzing biological fluids such as blood, it offers a non-invasive method of detecting cancer, tracking disease progression, and assessing treatment responses.
Table of Contents
- Global Liquid Biopsy Market Overview
- Key Market Drivers
- Increasing Incidence of Cancer and Chronic Diseases
- Advancements in Biomarker Technology
- Liquid Biopsy’s Shift Toward Non-invasive Diagnostics
- Regional Market Insights
- United States Liquid Biopsy Market
- Germany Liquid Biopsy Market
- China Liquid Biopsy Market
- Brazil Liquid Biopsy Market
- Recent Developments in Liquid Biopsy
- Product Segmentation
- Kits & Reagents
- Platforms & Instruments
- Services
- Application Areas
- Cancer Therapeutic Application
- Reproductive Health
- Other Therapeutic Areas
- Circulating Biomarkers
- Circulating Tumor Cells
- Circulating Tumor DNA
- Cell-Free DNA
- End-User Segmentation
- Hospitals
- Diagnostic Laboratories
- Point-of-Care Testing
- Academic Institutes
- Regional Breakdown
- Americas
- Europe
- Asia-Pacific
- Middle East & Africa
- Company Analysis
- Overview
- Recent Developments
- Revenue
Global Liquid Biopsy Market Overview
Liquid biopsy is a groundbreaking non-invasive diagnostic tool that allows healthcare providers to detect and monitor cancer and other diseases by analyzing biological fluids, primarily blood. Unlike traditional tissue biopsies, which require surgical procedures to obtain tissue samples, liquid biopsies leverage circulating biomarkers, such as cell-free DNA (cfDNA), circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and exosomes found in the bloodstream.
This market is driven by the growing preference for early cancer detection, minimal risk, and the ability to monitor disease progression in real-time. Liquid biopsies are essential for detecting minimal residual disease and cancer recurrence, making them a valuable tool in personalized medicine.
Key Market Drivers
Increasing Incidence of Cancer and Chronic Diseases
The rising global incidence of cancer is one of the primary drivers behind the growth of the liquid biopsy market. Cancer remains one of the most prevalent diseases worldwide, with an estimated 2.0 million new cases and 611,720 cancer-related deaths in the United States alone in 2024. The growing need for efficient, accurate, and minimally invasive diagnostic tools is increasing the demand for liquid biopsy technologies.
Additionally, liquid biopsies are gaining traction in the monitoring of chronic diseases, such as cardiovascular conditions and genetic disorders, further expanding the scope of this diagnostic method.
Advancements in Biomarker Technology
Technological innovations in biomarker discovery, especially with the use of Next-Generation Sequencing (NGS), circulating tumor DNA (ctDNA), and exosome profiling, have significantly improved the sensitivity and specificity of liquid biopsies. These advancements allow for earlier disease detection, real-time tracking of treatment response, and identification of actionable genetic mutations.
A notable example is the partnership between Hitachi High-Tech Corporation and Gencurix, Inc., established in August 2024. This collaboration aims to integrate in vitro diagnostic products with biomarker discovery services, advancing the field of cancer molecular diagnostics.
Shift Toward Non-invasive Diagnostic Methods
As patients and healthcare providers increasingly demand non-invasive methods of diagnosis, liquid biopsies are becoming a preferred choice. They involve minimal risk, require little to no recovery time, and can be performed repeatedly, making them suitable for patients with advanced-stage cancer who may not be eligible for traditional biopsy procedures. This shift in preference is fostering the widespread adoption of liquid biopsy technologies.
Regional Market Insights
United States Liquid Biopsy Market
The United States holds a dominant position in the global liquid biopsy market, driven by its high incidence of cancer, robust healthcare infrastructure, and leading biotechnology companies. The FDA’s approval of liquid biopsy technologies, along with substantial investments in R&D, have further bolstered the market. Notable developments include the acquisition of cancer diagnostic assets by Myriad Genetics, Inc. in February 2024, which aims to enhance their liquid biopsy offerings for personalized cancer treatment.
Germany Liquid Biopsy Market
Germany is a key player in the European liquid biopsy market due to its strong healthcare system and investments in biotechnology. The country’s focus on precision medicine and molecular diagnostics has facilitated the integration of liquid biopsy technologies into clinical settings. Noteworthy innovations, such as PreAnalytiX GmbH's launch of the PAXgene Urine Liquid Biopsy Set in September 2024, exemplify Germany's commitment to advancing cancer diagnostics.
China Liquid Biopsy Market
China’s liquid biopsy market is expanding rapidly, supported by the government’s focus on improving healthcare infrastructure and access to advanced diagnostic tools. The rising cancer prevalence in the country is fueling the demand for early detection methods. Regulatory approvals, such as the National Medical Products Administration’s approval of sunvozertinib in August 2023, are helping to increase liquid biopsy adoption for cancer diagnosis.
Brazil Liquid Biopsy Market
Brazil is the leader in Latin America’s liquid biopsy market, driven by increased healthcare awareness and greater access to innovative medical technologies. With one of the highest cancer prevalence rates in the region, Brazil’s growing demand for early detection methods further supports the market for liquid biopsy technologies.
Recent Developments in Liquid Biopsy
- F. Hoffmann-La Roche Ltd.: In October 2020, the company received FDA approval for its liquid biopsy test as a companion diagnostic (CDx) for non-small cell lung cancer (NSCLC). This approval has led to greater adoption of liquid biopsy technologies in clinical cancer treatment.
- Guardant Health: In January 2023, Guardant Health received FDA approval for the Guardant360 CDx test as a companion diagnostic for ESR1 mutant breast cancer diagnosis, marking a significant milestone in liquid biopsy technology.
- Thermo Fisher Scientific: In 2023, Thermo Fisher released digital PCR liquid biopsy assays, enhancing the ability to monitor measurable residual disease (MRD) and advancing cancer research.
Product Segmentation
- Kits & Reagents: Diagnostic kits and reagents used in liquid biopsy procedures, essential for detecting biomarkers such as ctDNA and cfDNA.
- Platforms & Instruments: Devices and equipment used for processing and analyzing liquid biopsy samples, including Next-Generation Sequencers (NGS) and PCR systems.
- Services: Service offerings that include genetic testing and diagnostic consultations, as well as clinical trials and personalized medicine services.
Application Areas
- Cancer Therapeutic Application: Liquid biopsy plays a crucial role in early cancer detection, monitoring treatment response, and tracking disease recurrence.
- Reproductive Health: Liquid biopsies are increasingly being used for prenatal testing and detecting genetic abnormalities.
- Other Therapeutic Areas: Liquid biopsy technologies are also applied in monitoring organ transplant rejection, detecting infectious diseases, and diagnosing various genetic conditions.
Circulating Biomarkers
- Circulating Tumor Cells (CTCs): Cells shed by tumors into the bloodstream that can be analyzed for cancer diagnosis and monitoring.
- Circulating Tumor DNA (ctDNA): Fragments of DNA released by tumors that can be analyzed to detect mutations and monitor disease progression.
- Cell-free DNA (cfDNA): DNA released into the bloodstream, used for non-invasive genetic testing and disease detection.
End-User Segmentation
- Hospitals: Major end-users of liquid biopsy technologies for routine diagnostics and cancer monitoring.
- Diagnostic Laboratories: Laboratories specializing in molecular diagnostics, which play a central role in the liquid biopsy market.
- Point-of-care Testing: Emerging trend for liquid biopsy testing in outpatient and home-based settings.
- Academic Institutes: Research institutions contributing to innovation in liquid biopsy technologies.
Company Analysis
- F. Hoffmann-La Roche Ltd.: A leader in liquid biopsy diagnostics, Roche offers various tests and assays for cancer detection and monitoring.
- Guardant Health: Specializes in liquid biopsy assays like Guardant360 CDx, used for precision oncology.
- Thermo Fisher Scientific: Offers a range of liquid biopsy products, including digital PCR assays for cancer research.
- Bio-Rad Laboratories: Known for its ddPCR technology used in liquid biopsy for detecting cancer and monitoring treatment response.
- Illumina, Inc.: Provides genomic profiling solutions, including TruSight Oncology ctDNA assays for liquid biopsy testing.
New Publish Blog :
Top 10 Leading Liquid Biopsy Companies in 2025
Top Augmented Reality Companies Shaping the Future of AR
Top Ginger Companies Shaping the Global Market in 2025
Conclusion
The global liquid biopsy market is poised for substantial growth, driven by the increasing demand for non-invasive cancer diagnostics, advancements in technology, and a shift toward personalized medicine. With significant contributions from key players like Roche, Thermo Fisher, and Guardant Health, the market is evolving rapidly, paving the way for better, more efficient cancer care.
About the Company:
Renub Research is a Market Research and Consulting Company. We have more than 15 years of experience especially in international Business-to-Business Researches, Surveys and Consulting. We provide a wide range of business research solutions that helps companies in making better business decisions. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses. Our wide clientele comprises major players in Healthcare, Travel and Tourism, Food Beverages, Power Energy, Information Technology, Telecom Internet, Chemical, Logistics Automotive, Consumer Goods Retail, Building, and Construction, Agriculture. Our core team is comprised of experienced people holding graduate, postgraduate, and Ph.D. degrees in Finance, Marketing, Human Resource, Bio-Technology, Medicine, Information Technology, Environmental Science, and many more.
Media Contact:
Company Name: Renub Research
Contact Person: Rajat Gupta, Marketing Manager
Phone No: +91-120-421-9822 (IND) | +1-478-202-3244 (USA)
Email: mailto:rajat@renub.com
